150 related articles for article (PubMed ID: 38167641)
21. Lymph node status in inflammatory breast cancer.
Wecsler JS; Tereffe W; Pedersen RC; Sieffert MR; Mack WJ; Cui H; Russell CA; Woods RR; Viscusi RK; Sener SF; Lang JE
Breast Cancer Res Treat; 2015 May; 151(1):113-20. PubMed ID: 25846421
[TBL] [Abstract][Full Text] [Related]
22. The Association between ER, PR, HER2, and ER-/PR+ Expression and Lung Cancer Subsequent in Breast Cancer Patients: A Retrospective Cohort Study Based on SEER Database.
Shao HY; Hao BT; Gao FX
Breast J; 2023; 2023():7028189. PubMed ID: 38021219
[TBL] [Abstract][Full Text] [Related]
23. Age related influence of triple receptor status on metastatic breast cancer post relapse survival.
Todorovic-Rakovic N; Neskovic-Konstantinovic Z
J BUON; 2013; 18(4):851-8. PubMed ID: 24344008
[TBL] [Abstract][Full Text] [Related]
24. Negative estrogen receptors and positive progesterone receptors breast cancers.
Delvallée J; Etienne C; Arbion F; Vildé A; Body G; Ouldamer L
J Gynecol Obstet Hum Reprod; 2021 Feb; 50(2):101928. PubMed ID: 33022450
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.
Liu J; Chen K; Jiang W; Mao K; Li S; Kim MJ; Liu Q; Jacobs LK
J Cancer Res Clin Oncol; 2017 Jan; 143(1):161-168. PubMed ID: 27704268
[TBL] [Abstract][Full Text] [Related]
26. Influence of progesterone receptor on metastasis and prognosis in breast cancer patients with negative HER-2.
Xiao Y; Li J; Wu Z; Zhang X; Ming J
Gland Surg; 2022 Jan; 11(1):77-90. PubMed ID: 35242671
[TBL] [Abstract][Full Text] [Related]
27. [Influence of the HLDF differentiation factor on the production of cytokines by bio-tissues of breast tissue in its non-malignant diseases and in invasive carcinoma of a non-specific type].
Autenshlyus AI; Studenikina AA; Mikhaylova YS; Proskura AV; Varaksin NA; Sidorov SV; Bogachuk AP; Lipkin VM; Lyakhovich VV
Biomed Khim; 2020 Nov; 66(6):485-493. PubMed ID: 33372907
[TBL] [Abstract][Full Text] [Related]
28. Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'.
Charafe-Jauffret E; Tarpin C; Bardou VJ; Bertucci F; Ginestier C; Braud AC; Puig B; Geneix J; Hassoun J; Birnbaum D; Jacquemier J; Viens P
J Pathol; 2004 Mar; 202(3):265-73. PubMed ID: 14991891
[TBL] [Abstract][Full Text] [Related]
29. The Case to Case Comparison of Hormone Receptors and HER2 Status between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis.
Sujarittanakarn S; Himakhun W; Worasawate W; Prasert W
Asian Pac J Cancer Prev; 2020 Jun; 21(6):1559-1565. PubMed ID: 32592349
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant chemotherapy could benefit early-stage ER/PR positive mucinous breast cancer: A SEER-based analysis.
Gao HF; Li WP; Zhu T; Yang CQ; Yang M; Zhang LL; Ji F; Cheng MY; Li JQ; Wang K
Breast; 2020 Dec; 54():79-87. PubMed ID: 32947149
[TBL] [Abstract][Full Text] [Related]
31. Hormonal Receptor, Human Epidermal Growth Factor and Its Association with Breast Cancer Tumor Characteristics in Albania.
Pajenga E; Rexha T; Çeliku S; Ugrinska A; Bejtja G
Cent Eur J Public Health; 2016 Sep; 24(3):171-175. PubMed ID: 27760283
[TBL] [Abstract][Full Text] [Related]
32. Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country.
Subramaniam S; Bhoo-Pathy N; Taib NA; Tan GH; See MH; Jamaris S; Ho GF; Looi LM; Yip CH
World J Surg; 2015 Oct; 39(10):2450-8. PubMed ID: 26138872
[TBL] [Abstract][Full Text] [Related]
33. GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer.
Arias-Pulido H; Royce M; Gong Y; Joste N; Lomo L; Lee SJ; Chaher N; Verschraegen C; Lara J; Prossnitz ER; Cristofanilli M
Breast Cancer Res Treat; 2010 Aug; 123(1):51-8. PubMed ID: 19902352
[TBL] [Abstract][Full Text] [Related]
34. Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study.
Purdie CA; Quinlan P; Jordan LB; Ashfield A; Ogston S; Dewar JA; Thompson AM
Br J Cancer; 2014 Feb; 110(3):565-72. PubMed ID: 24300977
[TBL] [Abstract][Full Text] [Related]
35. Clinical Features and Prognosis Analysis of Hormone Receptor-Positive, HER2-Negative Breast Cancer with Differential Expression Levels of Estrogen and Progesterone Receptors: A 10-Year Retrospective Study.
Liu J; Gan M; Lin Z; Deng Q; Deng J; Zeng B; Shi Y; Ming J
Breast J; 2022; 2022():5469163. PubMed ID: 36531979
[TBL] [Abstract][Full Text] [Related]
36. ER
Arciero CA; Guo Y; Jiang R; Behera M; O'Regan R; Peng L; Li X
Clin Breast Cancer; 2019 Aug; 19(4):236-245. PubMed ID: 30846407
[TBL] [Abstract][Full Text] [Related]
37. Lack of either estrogen or progesterone receptor expression is associated with poor survival outcome among luminal A breast cancer subtype.
Park S; Park BW; Kim TH; Jeon CW; Kang HS; Choi JE; Hwang KT; Kim IC
Ann Surg Oncol; 2013 May; 20(5):1505-13. PubMed ID: 23192228
[TBL] [Abstract][Full Text] [Related]
38. Single hormone receptor-positive breast cancer patients experienced poor survival outcomes: a systematic review and meta-analysis.
Wu N; Fu F; Chen L; Lin Y; Yang P; Wang C
Clin Transl Oncol; 2020 Apr; 22(4):474-485. PubMed ID: 31222450
[TBL] [Abstract][Full Text] [Related]
39. The Prognosis of Single Hormone Receptor-Positive Breast Cancer Stratified by HER2 Status.
Zhao H; Gong Y
Front Oncol; 2021; 11():643956. PubMed ID: 34079755
[TBL] [Abstract][Full Text] [Related]
40. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
Li J; Xia Y; Wu Q; Zhu S; Chen C; Yang W; Wei W; Sun S
Oncotarget; 2017 Jul; 8(30):49370-49379. PubMed ID: 28472761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
